TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

NCT06014073 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non Hodgkin's Lymphoma

Interventions

BIOLOGICAL: TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]
[object Object]